Fig. 4.
Fig. 4. CD40L message is detected in RNAs prepared from CLL samples. Fresh CLL B cells (1 × 107) purified from the peripheral blood of 2 patients were exposed overnight in culture to media alone, to SAC and IL-2 (1:60,000 and 40 U/mL), to PMA and ionomycin (10 ng/mL and 1.25 μg/mL), or to IL-4 (10 ng/mL). After 18 hours, RNAs were isolated, cDNAs were prepared by reverse transcriptase, and CD40L sequences were amplified (A). The RNAs analyzed are as follows: lane 1, CLL case no. 15 B cells with media; lane 2, with IL-2 and SAC; lane 3, with PMA and ionomycin; lane 4, with IL-4; lane 5, CLL case no. 16 B cells with media; lane 6, with IL-2 and SAC; lane 7, with PMA and ionomycin; lane 8, with IL-4. Positive and negative controls for detection of CD40L RNA sequences included RNAs from 1 × 107 D1.1 cells (lane 10, Jurkat mutants that constitutively express CD40L) and Ramos Burkitt's lymphoma B cells (lane 9, these do not express CD40L). The cDNA preparations were evaluated by amplification of GAPDH sequences (B).

CD40L message is detected in RNAs prepared from CLL samples. Fresh CLL B cells (1 × 107) purified from the peripheral blood of 2 patients were exposed overnight in culture to media alone, to SAC and IL-2 (1:60,000 and 40 U/mL), to PMA and ionomycin (10 ng/mL and 1.25 μg/mL), or to IL-4 (10 ng/mL). After 18 hours, RNAs were isolated, cDNAs were prepared by reverse transcriptase, and CD40L sequences were amplified (A). The RNAs analyzed are as follows: lane 1, CLL case no. 15 B cells with media; lane 2, with IL-2 and SAC; lane 3, with PMA and ionomycin; lane 4, with IL-4; lane 5, CLL case no. 16 B cells with media; lane 6, with IL-2 and SAC; lane 7, with PMA and ionomycin; lane 8, with IL-4. Positive and negative controls for detection of CD40L RNA sequences included RNAs from 1 × 107 D1.1 cells (lane 10, Jurkat mutants that constitutively express CD40L) and Ramos Burkitt's lymphoma B cells (lane 9, these do not express CD40L). The cDNA preparations were evaluated by amplification of GAPDH sequences (B).

Close Modal

or Create an Account

Close Modal
Close Modal